The DOI matches its Crossref record; 96 of the 98 references it cites were found in a registry or an index.
Progress report on new antiepileptic drugs: A summary of the Eleventh Eilat Conference (EILAT XI)
Open accessAbstract
The Eleventh Eilat Conference on New Antiepileptic Drugs (AEDs)-EILAT XI, took place in Eilat, Israel from the 6th to 10th of May 2012. About 100 basic scientists, clinical pharmacologists and neurologists from 20 countries attended the conference, whose main themes included "Indications overlapping with epilepsy" and "Securing the successful development of an investigational antiepileptic drug in the current environment". Consistent with previous formats of this conference, a large part of the program was devoted to a review of AEDs in development, as well as updates on AEDs introduced since 1994. Like the EILAT X report, the current manuscript focuses only on the preclinical and clinical pharmacology of AEDs that are currently in development. These include brivaracetam, 2-deoxy-glucose, ganaxolone, ICA-105665, imepitoin, NAX 801-2, perampanel and other AMPA receptor antagonists, tonabersat, valnoctamide and its homologue sec-propylbutylacetamide (SPD), VX-765 and YK3089. Since the previous Eilat conference, retigabine (ezogabine) has been marketed and four newer AEDs in development (NAX 810-2, SPD, tonabersat and VX-765) are included in this manuscript.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although, there is an abundance of diverse antiepileptic drugs, most of them exert their actions by inhibition of the voltage-gated sodium or calcium channels or by potentiation of the GABA-mediated synaptic transmission [11], which results in a symptomatic approach in most cases; the goal of these drugs is to eliminate or at least reduce the number and/or severity of seizures.”
From Hippocampal neuro-networks and dendritic spine perturbations in epileptogenesis are attenuated by neuroprotectin D1 (2015) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610
The neurobiology of antiepileptic drugs
Rogawski, M. A., & Löscher, W. (2004) · Nature reviews. Neuroscience · doi:10.1038/nrn1430 · Cited by 1,243
Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites
Hosie, A. M., Wilkins, M. E., da Silva, H. M. A., & Smart, T. G. (2006) · Nature · doi:10.1038/nature05324 · Cited by 752
Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy
Barton, M. E., Klein, B. D., Wolf, H. H., & White, H. S. (2001) · Epilepsy Research · doi:10.1016/s0920-1211(01)00302-3 · Cited by 614
Self-citationMehta, A. K., & Ticku, M. K. (1999) · Brain Research Reviews · doi:10.1016/s0165-0173(98)00052-6 · Cited by 613
The role of cytokines in the pathophysiology of epilepsy
Vezzani, A., Balosso, S., & Ravizza, T. (2008) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2008.03.009 · Cited by 564
Key factors in the discovery and development of new antiepileptic drugs
Bialer, M., & White, H. S. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2997 · Cited by 544
Self-citation(2004) · Wiley eBooks · doi:10.1002/9780470752463 · Cited by 509
Adjunctive perampanel for refractory partial-onset seizures
French, J. A., Krauss, G. L., Biton, V., Squillacote, D., Yang, H., Laurenza, A., Kumar, D., Rogawski, M. A., Campanille, V., Floridia, J., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182635735 · Cited by 478
Progress report on new antiepileptic drugs: A summary of the Eigth Eilat Conference (EILAT VIII)
Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H., Perucca, E., & Tomson, T. (2006) · Epilepsy Research · doi:10.1016/j.eplepsyres.2006.10.008 · Cited by 477
Self-citation
Research works printed but not linked: 13
- Biton, 2009, Brivaracetam as adjunctive treatment of refractory partial-onset seizures in adults: results from two randomized, double-blind, placebo-controlled trials, Epilepsia, 50, 106
- Brodsky, 2007, Safety and tolerability of brivaracetam (ucb 34714) as adjunctive treatment in adults with refractory partial-onset seizures, Epilepsia, 48, 342
- Kwan, 2009, Safety and tolerability of brivaracetam as adjunctive treatment in adults with refractory epilepsy: randomized, double-blind, placebo-controlled trial, Epilepsia, 50, 107
- Niespodziany, 2009, Brivaracetam modulates Na+ currents expressed in a neuroblastoma cell line compared with carbamazepine, Epilepsia, 50, 107
- Rostock, 1998, AWD 131-138 is a potential novel anxiolytic without sedation and amnesia: a comparison with diazepam and buspirone, Naunyn-Schmied. Arch. Pharmacol., 358, R68
- Sargentini-Maier, 2008, Pharmacokinetics, safety and tolerability of brivaracetam in healthy elderly subjects, Epilepsia, 49, 452
- Stafstrom, 2007, 2-Deoxyglucose effects on spatial learning and exploratory behavior in rodents, Epilepsia, 48, 299
- Stockis, 2009, Interaction study between brivaracetam and a combination oral contraceptive, Epilepsia, 50, 96
- Sutula, 2008, Dose-response and time course of action of disease-modifying effects of 2DG on kindling progression: effectiveness of administration after seizures, Epilepsia, 49, 382
- Tober, 1998, AWD 131-138: a derivative of a series of imidazolinones with anticonvulsant activity, Naunyn-Schmied. Arch. Pharmacol., 358, R68
- Tober, 1999, Anticonvulsant activity of AWD 131-138 in genetic animal models of epilepsy, Naunyn-Schmied. Arch. Pharmacol., 359, R97
- Van Paesschen, 2007, Efficacy and tolerability of 50 and 150mg/day brivaracetam (UCB 34714) as adjunctive treatment in adults with refractory partial onset epilepsy, Epilepsia, 48, 329
- Wasterlain, 2009, Short-term and long-term effects of brivaracetam in an animal model of status epilepticus, Epilepsia, 50, 13
Cited by
Sorted by citations
Löscher, W., Potschka, H., Sisodiya, S. M., & Vezzani, A. (2020) · Pharmacological Reviews · doi:10.1124/pr.120.019539 · Cited by 967
Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy
Vezzani, A., Balosso, S., & Ravizza, T. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0217-x · Cited by 928
New avenues for anti-epileptic drug discovery and development
Löscher, W., Klitgaard, H., Twyman, R. E., & Schmidt, D. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4126 · Cited by 696
Krauss, G. L., Klein, P., Brandt, C., Lee, S. K., Milanov, I. G., Milovanović, M., Steinhoff, B. J., & Kamin, M. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30399-0 · Cited by 347
Pathogenesis of acute stroke and the role of inflammasomes
Fann, D. Y., Lee, S.-Y., Manzanero, S., Chunduri, P., Sobey, C. G., & Arumugam, T. V. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2013.09.004 · Cited by 334
The role of inflammasomes in kidney disease
Komada, T., & Muruve, D. A. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0158-z · Cited by 317
Kaushal, V, Dye, R., Pakavathkumar, P., Foveau, B., Flores, J., Hyman, B., Ghetti, B., Koller, B. H., & LeBlanc, A. C. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2015.16 · Cited by 297
Flores, J., Noël, A., Foveau, B., Lynham, J., Lecrux, C., & LeBlanc, A. C. (2018) · Nature Communications · doi:10.1038/s41467-018-06449-x · Cited by 288
van Vliet, E. A., Aronica, E., Vezzani, A., & Ravizza, T. (2017) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12444 · Cited by 267
Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures
Chung, S. S., French, J. A., Kowalski, J., Krauss, G. L., Lee, S. K., Maciejowski, M., Rosenfeld, W. E., Sperling, M. R., Mizne, S., & Kamin, M. (2020) · Neurology · doi:10.1212/wnl.0000000000009530 · Cited by 248
Therapeutic modulation of inflammasome pathways
Chauhan, D., Walle, L. V., & Lamkanfi, M. (2020) · Immunological Reviews · doi:10.1111/imr.12908 · Cited by 219
Sperling, M. R., Klein, P., Aboumatar, S., Gelfand, M. A., Halford, J. J., Krauss, G. L., Rosenfeld, W. E., Vossler, D. G., Wechsler, R. T., Borchert, L. D., et al. (2020) · Epilepsia · doi:10.1111/epi.16525 · Cited by 218
Anti-Inflammatory Small Molecules To Treat Seizures and Epilepsy: From Bench to Bedside
Dey, A., Xu, K., Qiu, J., Du, Y., & Jiang, J. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.03.001 · Cited by 214
A long way to go: caspase inhibitors in clinical use
Dhani, S., Zhao, Y., & Zhivotovsky, B. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04240-3 · Cited by 216
Iori, V., Iyer, A. M., Ravizza, T., Beltrame, L., Paracchini, L., Marchini, S., Cerovic, M., Hill, C., Ferrari, M., Zucchetti, M., et al. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.12.007 · Cited by 190
Self-citationPatsalos, P. N. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0087-0 · Cited by 185
Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII)
Bialer, M., Johannessen, S. I., Levy, R. H., Perucca, E., Tomson, T., & White, H. S. (2015) · Epilepsy Research · doi:10.1016/j.eplepsyres.2015.01.001 · Cited by 174
Self-citationNakamura, M., Cho, J., Shin, H., & Jang, I. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.05.007 · Cited by 166
Inflammasome components as new therapeutic targets in inflammatory disease
Coll, R. C., & Schroder, K. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01075-9 · Cited by 175
Paugh, S. W., Bonten, E. J., Savic, D., Ramsey, L. B., Thierfelder, W. E., Gurung, P., Malireddi, R. K. S., Actis, M., Mayasundari, A., Min, J., et al. (2015) · Nature Genetics · doi:10.1038/ng.3283 · Cited by 164
Neuroactive steroids for the treatment of status epilepticus
Rogawski, M. A., Loya, C. M., Reddy, K., Żółkowska, D., & Lossin, C. (2013) · Epilepsia · doi:10.1111/epi.12289 · Cited by 155
Clinical Management of Drug Resistant Epilepsy: A Review on Current Strategies
Guery, D., & Rheims, S. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s256699 · Cited by 165
Bialer, M., Johannessen, S. I., Koepp, M. J., Levy, R. H., Perucca, E., Perucca, P., Tomson, T., & White, H. S. (2020) · Epilepsia · doi:10.1111/epi.16725 · Cited by 148
Self-citationAstrocytes as Guardians of Neuronal Excitability: Mechanisms Underlying Epileptogenesis
Verhoog, Q. P., Holtman, L., Aronica, E., & van Vliet, E. A. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.591690 · Cited by 149
The Interconnected Mechanisms of Oxidative Stress and Neuroinflammation in Epilepsy
Parsons, A. L. M., Bucknor, E. M. V., Castroflorio, E., Soares, T. R., Oliver, P. L., & Rial, D. (2022) · Antioxidants · doi:10.3390/antiox11010157 · Cited by 147
Positive allosteric modulation of GABAA receptors by a novel antiepileptic drug cenobamate
Sharma, R., Nakamura, M., Neupane, C., Jeon, B. H., Shin, H., Melnick, S. M., Glenn, K., Jang, I., & Park, J. B. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173117 · Cited by 135
Pediatric super‐refractory status epilepticus treated with allopregnanolone
Broomall, E. M., Natale, J. E., Grimason, M., Goldstein, J. L., Smith, C. M., Chang, C. H., Kanes, S., Rogawski, M. A., & Wainwright, M. S. (2014) · Annals of Neurology · doi:10.1002/ana.24295 · Cited by 120
Bialer, M., Johannessen, S. I., Levy, R. H., Perucca, E., Tomson, T., & White, H. S. (2017) · Epilepsia · doi:10.1111/epi.13634 · Cited by 110
Self-citationNeuroinflammation microenvironment sharpens seizure circuit
Villasana‐Salazar, B., & Vezzani, A. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106027 · Cited by 110
Amino Acids in the Development of Prodrugs
Vale, N., Ferreira, A., Matos, J., Fresco, P., & Gouveia, M. J. (2018) · Molecules · doi:10.3390/molecules23092318 · Cited by 111
Jimenez-Mateos, E. M., Arribas-Blazquez, M., Sanz-Rodriguez, A., Concannon, C., Olivos-Ore, L. A., Reschke, C. R., Mooney, C. M., Mooney, C., Lugara, E., Morgan, J., et al. (2015) · Scientific Reports · doi:10.1038/srep17486 · Cited by 103
Neuroinflammation in Post-Traumatic Epilepsy: Pathophysiology and Tractable Therapeutic Targets
Sharma, R., Leung, W. L., Zamani, A., O'Brien, T. J., Casillas-Espinosa, P. M., & Semple, B. D. (2019) · Brain Sciences · doi:10.3390/brainsci9110318 · Cited by 104
Ravizza, T., & Vezzani, A. (2018) · Epilepsia Open · doi:10.1002/epi4.12242 · Cited by 96
ATPergic signalling during seizures and epilepsy
Engel, T., Alves, M., Sheedy, C., & Henshall, D. C. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.11.001 · Cited by 97
Ganaxolone improves behavioral deficits in a mouse model of post-traumatic stress disorder
Pinna, G., & Rasmusson, A. M. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00256 · Cited by 94
Štrac, D. Š., Pivac, N., Smolders, I. J., Fogel, W. A., Deurwaerdère, P. D., & Giovanni, G. D. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00492 · Cited by 94
Kaminski, R. M., Rogawski, M. A., & Klitgaard, H. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0266-1 · Cited by 90
He, Z., An, S., Chen, J., Zhang, S., Tan, C., Yu, J., Ye, H., Wu, Y., Yuan, J. X., Wu, J., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2007773117 · Cited by 87
Development and pharmacologic characterization of the rat 6 Hz model of partial seizures
Metcalf, C. S., West, P. J., Thomson, K. E., Edwards, S. F., Smith, M. D., White, H. S., & Wilcox, K. S. (2017) · Epilepsia · doi:10.1111/epi.13764 · Cited by 84
Self-citationGuignet, M. A., Campbell, A., & White, H. S. (2020) · Epilepsia · doi:10.1111/epi.16718 · Cited by 83
Self-citationAltered expression of δGABAA receptors in health and disease
Whissell, P. D., Lecker, I., Wang, D.-S., Yu, J., & Orser, B. A. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.08.003 · Cited by 81
Renal macrophages and NLRP3 inflammasomes in kidney diseases and therapeutics
Islamuddin, M., & Qin, X.-B. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01996-3 · Cited by 81
Kim, Y., Griffin, J. M., Nor, M. N. M., Zhang, J., Freestone, P. S., Danesh-Meyer, H. V., Rupenthal, I. D., Acosta, M. L., Nicholson, L. F. B., O’Carroll, S. J., et al. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0536-9 · Cited by 81
Li, Q., Dai, Z., Cao, Y., & Wang, L. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.03.202 · Cited by 78
Modelling epilepsy in the mouse: challenges and solutions
Marshall, G. F., Gonzalez‐Sulser, A., & Abbott, C. M. (2021) · Disease Models & Mechanisms · doi:10.1242/dmm.047449 · Cited by 80
The role of inflammation in epileptogenesis
Meng, F., & Yao, L. (2020) · Acta Epileptologica · doi:10.1186/s42494-020-00024-y · Cited by 75
The ups and downs of alkyl‐carbamates in epilepsy therapy: How does cenobamate differ?
Löscher, W., Sills, G. J., & White, H. S. (2021) · Epilepsia · doi:10.1111/epi.16832 · Cited by 71
Self-citationAdvances in anti-epileptic drug testing
Krasowski, M. D., & McMillin, G. A. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.06.002 · Cited by 71
Trinka, E., & Brigo, F. (2014) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000067 · Cited by 70
Adjunctive Cenobamate for Focal-Onset Seizures in Adults: A Systematic Review and Meta-Analysis
Lattanzi, S., Trinka, E., Zaccara, G., Striano, P., Giovane, C. D., Silvestrini, M., & Brigo, F. (2020) · CNS Drugs · doi:10.1007/s40263-020-00759-9 · Cited by 69
Neurovascular unit dysfunction as a mechanism of seizures and epilepsy during aging
van Vliet, E. A., & Marchi, N. (2022) · Epilepsia · doi:10.1111/epi.17210 · Cited by 69
Cx43 hemichannels contribute to astrocyte-mediated toxicity in sporadic and familial ALS
Almad, A. A., Taga, A., Joseph, J., Gross, S. K., Welsh, C., Patankar, A. G., Richard, J., Rust, K., Pokharel, A., Plott, C. F., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2107391119 · Cited by 68
A resurging boom in new drugs for epilepsy and brain disorders
Younus, I., & Reddy, D. S. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1386553 · Cited by 83
Validation of a Preclinical Drug Screening Platform for Pharmacoresistant Epilepsy
Barker‐Haliski, M. L., Johnson, K. J., Billingsley, P., Huff, J. L., Handy, L. J., Khaleel, R., Lu, Z., Mau, M. J., Pruess, T. H., Rueda, C. B., et al. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2227-7 · Cited by 63
Eimon, P. M., Ghannad‐Rezaie, M., Rienzo, G. D., Allalou, A., Wu, Y., Gao, M., Roy, A., Skolnick, J., & Yanik, M. F. (2018) · Nature Communications · doi:10.1038/s41467-017-02404-4 · Cited by 65
Challal, S., Buenafe, O. E. M., Queiroz, E. F., Maljevic, S., Marcourt, L., Bock, M., Kloeti, W., Dayrit, F. M., Harvey, A. L., Lerche, H., et al. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn5001342 · Cited by 62
Phosphorylation of GABAA receptors influences receptor trafficking and neurosteroid actions
Comenencia-Ortiz, E., Moss, S. J., & Davies, P. A. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3617-z · Cited by 65
Żółkowska, D., Wu, C., & Rogawski, M. A. (2018) · Epilepsia · doi:10.1111/epi.13999 · Cited by 61
Tonic GABAA Receptors as Potential Target for the Treatment of Temporal Lobe Epilepsy
Schipper, S., Aalbers, M. W., Rijkers, K., Swijsen, A., Rigo, J., Hoogland, G., & Vles, J. S. H. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9423-8 · Cited by 59
Action of antiepileptic drugs on neurons
Kobayashi, K., Endoh, F., Ohmori, I., & Akiyama, T. (2019) · Brain and Development · doi:10.1016/j.braindev.2019.07.006 · Cited by 56
Involvement of gap junction channels in the pathophysiology of migraine with aura
Sarrouilhe, D., Dejean, C., & Mesnil, M. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00078 · Cited by 56
Stockis, A., Watanabe, S., Rouits, E., Matsuguma, K., & Irie, S. (2014) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-14-rg-010 · Cited by 56
Israelov, H., Ravid, O., Atrakchi, D., Rand, D., Goldman, S. E., Bresler, Y., Twitto‐Greenberg, R., Omesi, L., Zaltsman, S. L., Gosselet, F., et al. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01927-w · Cited by 53
Insights into Structural Modifications of Valproic Acid and Their Pharmacological Profile
Mishra, M., Kukal, S., Paul, P. R., Bora, S., Singh, A., Kukreti, S., Saso, L., Muthusamy, K., Hasija, Y., & Kukreti, R. (2021) · Molecules · doi:10.3390/molecules27010104 · Cited by 61
Research Progress on the Role of Inflammasomes in Kidney Disease
Chi, K., Geng, X., Liu, C., Cai, G., & Hong, Q. (2020) · Mediators of Inflammation · doi:10.1155/2020/8032797 · Cited by 55
Inflammasome and Its Therapeutic Targeting in Rheumatoid Arthritis
Jiang, Q., Wang, X., Huang, E., Wang, Q., Wen, C., Yang, G., Lu, L., & Cui, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.816839 · Cited by 55
Bialer, M., Johannessen, S. I., Koepp, M. J., Levy, R. H., Perucca, E., Perucca, P., Tomson, T., & White, H. S. (2020) · Epilepsia · doi:10.1111/epi.16726 · Cited by 52
Self-citationPyroptosis and Intervertebral Disc Degeneration: Mechanistic Insights and Therapeutic Implications
Ge, Y., Chen, Y., Guo, C., Luo, H., Fu, F., Ji, W., Wu, C., & Ruan, H. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s382069 · Cited by 53
Suppression of the photoparoxysmal response in photosensitive epilepsy with cenobamate (YKP3089)
Trenité, D. G. A. K.-N., DiVentura, B. D., Pollard, J. R., Krauss, G. L., Mizne, S., & French, J. A. (2019) · Neurology · doi:10.1212/wnl.0000000000007894 · Cited by 52
Successful treatment of adult Dravet syndrome patients with cenobamate
Makridis, K. L., Friedo, A., Kellinghaus, C., Losch, F., Schmitz, B., Boßelmann, C. M., & Kaindl, A. M. (2022) · Epilepsia · doi:10.1111/epi.17427 · Cited by 53
Flammer, J., Neziraj, T., Rüegg, S. J., & Pröbstel, A. (2023) · Drugs · doi:10.1007/s40265-022-01826-9 · Cited by 54
Campos, G., Fortuna, A. C., Falcão, A. C., & Alves, G. (2018) · Epilepsy Research · doi:10.1016/j.eplepsyres.2018.07.008 · Cited by 51
Early add‐on treatmentvsalternative monotherapy in patients with partial epilepsy
Semah, F., Thomas, P., Coulbaut, S., & Derambure, P. (2014) · Epileptic Disorders · doi:10.1684/epd.2014.0650 · Cited by 50
The Role of Pyroptosis in Ischemic and Reperfusion Injury of the Heart
Popov, S. V., Маслов, Л. Н., Naryzhnaya, N. V., Mukhomedzyanov, А. V., Krylatov, A. V., Tsibulnikov, S. Y., Ryabov, V. V., Cohen, M. V., & Downey, J. M. (2021) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484211027405 · Cited by 49
Targeting gap junction in epilepsy: Perspectives and challenges
Qin, L., Li, Q.-Q., Jia, J.-N., Liu, Z., Zhou, H., & Mao, X. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.068 · Cited by 49
The anticonvulsant retigabine is a subtype selective modulator of GABA A receptors
Treven, M., Koenig, X., Assadpour, E., Gantumur, E., Meyer, C., Hilber, K., Boehm, S., & Kubista, H. (2015) · Epilepsia · doi:10.1111/epi.12950 · Cited by 48
Ganaxolone: A New Treatment for Neonatal Seizures
Yawno, T., Miller, S. L., Bennet, L., Wong, F. Y., Hirst, J. J., Fahey, M. C., & Walker, D. W. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00246 · Cited by 48
Elizebath, R., Zhang, E. X., Coe, P., Gutierrez, E. G., Yang, J., & Krauss, G. L. (2021) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2021.107796 · Cited by 47
Tang, Y., Feng, B., Wang, Y., Sun, H., You, Y., Yu, J., Chen, B., Xu, C., Ruan, Y., Cui, S., et al. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15076 · Cited by 46
Systems biology, complexity, and the impact on antiepileptic drug discovery
Margineanu, D. G. (2013) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2013.08.029 · Cited by 43
Disease Modification in Epilepsy: From Animal Models to Clinical Applications
Barker‐Haliski, M. L., Friedman, D., French, J. A., & White, H. S. (2015) · Drugs · doi:10.1007/s40265-015-0395-9 · Cited by 45
Self-citationColeman, N., Nguyen, H. M., Cao, Z., Brown, B. M., Jenkins, D. P., Żółkowska, D., Chen, Y., Tanaka, B. S., Goldin, A. L., Rogawski, M. A., et al. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0305-y · Cited by 42
Targeting Kv7 Potassium Channels for Epilepsy
Perucca, E., & Taglialatela, M. (2025) · CNS Drugs · doi:10.1007/s40263-024-01155-3 · Cited by 43
Self-citationCiarlone, S. L., Wang, X., Rogawski, M. A., & Weeber, E. J. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.12.009 · Cited by 41
The Metabotropic Purinergic P2Y Receptor Family as Novel Drug Target in Epilepsy
Alves, M., Beamer, E. H., & Engel, T. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00193 · Cited by 41
Novel frontiers in epilepsy treatments: preventing epileptogenesis by targeting inflammation
D’Ambrosio, R., Eastman, C. L., Fattore, C., & Perucca, E. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/ern.13.54 · Cited by 41
Self-citationThe Role of Neuroinflammation in Post-traumatic Epilepsy
Sun, L., Shan, W., Yang, H., Liu, R., Wu, J., & Wang, Q. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.646152 · Cited by 41
The NLRP1 Inflammasome Induces Pyroptosis in Human Corneal Epithelial Cells
Griswold, A. R., Huang, H., & Bachovchin, D. A. (2022) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.63.3.2 · Cited by 40
Musto, A. E., Walker, C. P., Petasis, N. A., & Bazan, N. G. (2015) · PLOS ONE · doi:10.1371/journal.pone.0116543 · Cited by 39
Epilepsy in glioblastoma patients: basic mechanisms and current problems in treatment
Bruna, J., Miró, J., & Velasco, R. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.13.12 · Cited by 38
The NLRP3 Inflammasome in Neurodegenerative Disorders: Insights from Epileptic Models
Palumbo, L., Carinci, M., Guarino, A., Asth, L., Zucchini, S., Missiroli, S., Rimessi, A., Pinton, P., & Giorgi, C. (2023) · Biomedicines · doi:10.3390/biomedicines11102825 · Cited by 39
Useinovic, N., Maksimovic, S., Liechty, C., Cabrera, O. H., Quillinan, N., & Jevtović‐Todorović, V. (2022) · British Journal of Anaesthesia · doi:10.1016/j.bja.2022.05.008 · Cited by 36
Cenobamate in refractory epilepsy: Overview of treatment options and practical considerations
Schmitz, B., Lattanzi, S., Vonck, K. E. J., Kälviäinen, R. K., Nashef, L. A. M., & Ben‐Menachem, E. (2023) · Epilepsia Open · doi:10.1002/epi4.12830 · Cited by 35
Sun, Z., Gu, L., Wu, K., Wang, K., Ru, J., Yang, S., Wang, Z., Zhuge, Q., Huang, L., & Huang, S. (2020) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13400 · Cited by 34
Cao, Z., Zou, X., Cui, Y., Hulsizer, S., Lein, P. J., Wulff, H., & Pessah, I. N. (2015) · Molecular Pharmacology · doi:10.1124/mol.114.096701 · Cited by 34
Drug treatment in patients with newly diagnosed unprovoked seizures/epilepsy
Karlsson, L., Wettermark, B., & Tomson, T. (2014) · Epilepsy Research · doi:10.1016/j.eplepsyres.2014.03.004 · Cited by 33
Self-citationZaccara, G., & Schmidt, D. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.12.011 · Cited by 33
Recent progress of 1,3,4‐oxadiazoles as anticonvulsants: Future horizons
Nazar, S., Siddiqui, N., & Alam, O. (2020) · Archiv der Pharmazie · doi:10.1002/ardp.201900342 · Cited by 33
Kudin, A. P., Mawasi, H., Eisenkraft, A., Elger, C. E., Bialer, M., & Kunz, W. S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091912 · Cited by 33
Self-citationStockis, A., & Rolan, P. E. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.187 · Cited by 32
Metadata
- Authors
- Bialer, M., Johannessen, S. I., Levy, R. H., Perucca, E., Tomson, T., & White, H. S.
- Affiliations
- Hebrew University of Jerusalem (IL)
- Oslo University Hospital (NO)
- University of Washington (US)
- University of Pavia (IT)
- Karolinska Institutet (SE)
- University of Utah (US)
- Corresponding author
- Bialer, Meir
- Venue
- Epilepsy Research
- Publisher
- Elsevier BV
- Published
- 2013-01
- Volume
- 103
- Issue
- 1
- Pages
- 2-30
- ISSN
- 0920-1211 (ISSN-L)
- OpenAlex
- W2203865877
- Cited by
- 243
- References
- 98
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 14 · 2023: 13 · 2022: 20 · 2021: 17 · 2020: 32 · 2019: 12 · 2018: 10 · 2017: 19 · 2016: 17 · 2015: 23 · 2014: 24 · 2013: 20
- FWCI
- 2.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Epilepsy Research (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, cc-by-nc-nd)
- Funders
- National Institutes of Health
- UCB Pharma
- Topics
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- antiepileptic drugs, drug development, preclinical pharmacology, clinical pharmacology, brivaracetam, 2-deoxyglucose, ganaxolone, perampanel, AMPA receptor antagonists, tonabersat, retigabine, ezogabine, VX-765, epilepsy
- MeSH terms
- Animals, Anticonvulsants, Clinical Trials as Topic, Congresses as Topic, Epilepsy, Humans, Israel, Drugs, Investigational, Research Report
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
